Title |
Neutralizing IL-23 Is Superior to Blocking IL-17 in Suppressing Intestinal Inflammation in a Spontaneous Murine Colitis Model
|
---|---|
Published in |
Inflammatory Bowel Diseases, May 2015
|
DOI | 10.1097/mib.0000000000000353 |
Pubmed ID | |
Authors |
Ran Wang, Sumaira Z. Hasnain, Hui Tong, Indrajit Das, Alice Che-Hao Chen, Iulia Oancea, Martina Proctor, Timothy H. Florin, Rajaraman D. Eri, Michael A. McGuckin |
Abstract |
IL-23/T(H)17 inflammatory responses are regarded as central to the pathogenesis of inflammatory bowel disease, but clinically IL-17A antibodies have shown low efficacy and increased infections in Crohn's disease. Hence, we decided to closely examine the role of the IL-23/T(H)17 axis in 3 models of colitis. IL-17A(-/-) and IL-17Ra(-/-) T cells were transferred into Rag1 and RaW mice to assess the role of IL-17A-IL-17Ra signaling in T cells during colitis. In Winnie mice with spontaneous colitis due to an epithelial defect, we studied the progression of colitis in the absence of IL-17A and the efficacy of neutralizing antibodies against the IL-17A or IL-23p19 cytokines. In transfer colitis models, IL-17A-deficient T cells failed to ameliorate disease, and IL-17Ra-deficient T cells were more colitogenic than wild-type T cells. In Winnie mice with an epithelial defect and spontaneous T(H)17-dominated inflammation, genetic deficiency of IL-17A did not suppress initiation of colitis but limited colitis progression. Furthermore, inhibition of IL-17A by monoclonal antibodies did not reduce colitis severity. In contrast, neutralizing IL-23 using an anti-p19 antibody significantly alleviated both emerging and established colitis, downregulating T(H)17 proinflammatory cytokine expression and diminishing neutrophil infiltration. Our results support clinical studies showing that IL-17 neutralization is not therapeutic but that targeting IL-23 suppresses intestinal inflammation. Effects of IL-23 distinct from its effects on maturation of IL-17A-producing lymphocytes may underlie the protection from inflammatory bowel disease conveyed by hypomorphic IL-23 receptor polymorphisms and contribute to the efficacy of IL-23 neutralizing antibodies in inflammatory bowel disease. |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 24 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Researcher | 7 | 29% |
Student > Ph. D. Student | 4 | 17% |
Professor | 3 | 13% |
Student > Master | 2 | 8% |
Lecturer | 1 | 4% |
Other | 4 | 17% |
Unknown | 3 | 13% |
Readers by discipline | Count | As % |
---|---|---|
Immunology and Microbiology | 9 | 38% |
Medicine and Dentistry | 6 | 25% |
Agricultural and Biological Sciences | 2 | 8% |
Biochemistry, Genetics and Molecular Biology | 2 | 8% |
Computer Science | 1 | 4% |
Other | 0 | 0% |
Unknown | 4 | 17% |